Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arsenic trioxide
- Development stage
- Approved
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Intravenous, Topical, Intratumoral
01
Overview
Arsenic trioxide is an inorganic antineoplastic agent that serves as a cornerstone in the treatment of acute promyelocytic leukemia (APL). Its primary mechanism in APL involves binding to the PML-RARα fusion protein, inducing its degradation and subsequently promoting the differentiation and apoptosis of leukemic cells. Beyond hematologic malignancies, arsenic trioxide is being investigated for its activity in solid tumors as a radiosensitizer and anti-angiogenic agent. It exerts pleiotropic effects, including the induction of reactive oxygen species (ROS), inhibition of the Notch and Hedgehog signaling pathways, and activation of the intrinsic mitochondrial apoptotic pathway through caspase activation. It has been studied in various formulations, including intravenous solutions for systemic therapy and topical gels for cutaneous lesions.
- Brand names
- Trisenox
- Other names
- As2O3As-2O3As 2O3arsenic(III) oxidewhite arsenicarsenous acid anhydridearsenous oxide
02
Targets
TXNRD2 (Thioredoxin reductase 2)PML-RARA (PML-retinoic acid receptor alpha fusion protein)
Beyond the preview
Go deeper on arsenic trioxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arsenic trioxide.